First clinical trial initiated under Roche-Ascidian deal by June 30, 2025? | Binary | | | 6 months ago | |
When will Roche make the first milestone payment to Ascidian? | Categorical | | | 6 months ago | |
FDA grants Fast Track designation to Roche-Ascidian therapy by end of 2025? | Binary | | | 6 months ago | |
Ascidian achieves first milestone in Roche partnership by end of 2024? | Binary | | | 6 months ago | |
When will Roche-Ascidian RNA editing therapy receive Phase 1 trial approval? | Categorical | | | 6 months ago | |
Will Roche's obesity drug enter Phase II trials by end of 2024? | Binary | | | 7 months ago | |
FDA approval status of Roche's obesity drug by end of 2025 | Categorical | | | 7 months ago | |
Will CT-388 receive Fast Track designation by mid-2025? | Binary | | | 7 months ago | |
Will Roche's stock price increase by 10% in 3 months post Phase I announcement? | Binary | | | 7 months ago | |
Market adoption level of CT-388 within first year of approval | Categorical | | | 7 months ago | |
Market performance of Roche compared to competitors post Phase I announcement by end of 2024 | Categorical | | | 7 months ago | |
FDA approval status of CT-388 by end of 2025 | Categorical | | | 7 months ago | |
Will Roche advance CT-388 to Phase II by end of 2024? | Binary | | | 7 months ago | |
Will competing obesity drugs report similar or better results by end of 2024? | Binary | | | 7 months ago | |
New HPV Self-Testing Competitors in US by End of 2024? | Binary | | | 7 months ago | |
Major Insurance Coverage for Roche HPV Kit by Mid-2025? | Binary | | | 7 months ago | |
Regional adoption rates of Roche's HPV self-testing kit in the US by end of 2024? | Categorical | | | 7 months ago | |
What will be the market share of Roche's HPV self-testing kit in the US by end of 2024? | Categorical | | | 7 months ago | |
Will major health organizations endorse Roche's HPV self-testing by end of 2024? | Binary | | | 7 months ago | |
Will Roche's HPV self-testing kit see increased usage in the US by end of 2024? | Binary | | | 7 months ago | |
Will Monte Rosa's market cap double by end of 2025 following Novartis deal? | Binary | | | 2 months ago | |
Will Roche's share price rise by more than 10% by end of 2024? | Binary | | | 7 months ago | |
How will competitors respond to Roche's successful Phase I obesity drug trials by mid-2025? | Categorical | | | 7 months ago | |
Market performance of Roche's obesity drug in its first year post-approval | Categorical | | | 7 months ago | |
Will Roche acquire another biotech company by the end of 2024? | Binary | | | 7 months ago | |
How many pharmaceutical companies will initiate similar trials by the end of 2025? | Categorical | | | 7 months ago | |
Will Roche's market share in the obesity treatment sector increase by the end of 2025? | Binary | | | 7 months ago | |
What will be the global market size of dual GLP-1/GIP receptor agonists by 2026? | Categorical | | | 7 months ago | |
Will Roche initiate a Phase II trial for CT-388 by the end of 2024? | Binary | | | 7 months ago | |
Impact of Roche DIY HPV Kit on Screenings by End of 2025 | Categorical | | | 7 months ago | |
Roche DIY HPV Kit Sales Reach 1 Million by End of 2024? | Binary | | | 7 months ago | |
Market Share of Roche's HPV Kit in the US by End of 2024 | Categorical | | | 7 months ago | |
Impact of Roche's HPV self-testing on traditional pelvic exams by end of 2024? | Categorical | | | 7 months ago | |
Will Roche expand HPV self-testing kit availability to other countries by mid-2025? | Binary | | | 7 months ago | |
Will Roche complete Poseida acquisition by March 31, 2025? | Binary | | | 27 days ago | |
What will Poseida's stock price be by March 31, 2025? | Categorical | | | 27 days ago | |
What will be the total amount Roche pays for Poseida by end of 2025? | Categorical | | | 27 days ago | |
Will Poseida's CAR-T therapy receive FDA approval by end of 2025? | Binary | | | 27 days ago | |
Which company will dominate the subcutaneous PD-1/PD-L1 market by the end of 2025? | Categorical | | | 1 month ago | |
What will be Merck's revenue from subcutaneous Keytruda in 2025? | Categorical | | | 1 month ago | |
Will Monte Rosa receive first milestone payment from Novartis by end of 2025? | Binary | | | 2 months ago | |
What will be the peak sales of Genentech's oncology pipeline by December 31, 2025? | Categorical | | | 3 months ago | |
Will Recursion announce a new collaboration with a major pharmaceutical company by end of 2024? | Binary | | | 5 months ago | |
How much will Recursion's market cap increase by end of 2024? | Categorical | | | 5 months ago | |
Will Roche's stock (RHHBY) increase by 10% or more by the end of 2024? | Binary | | | 5 months ago | |
Which company's stock will perform the best by the end of 2024: Roche (RHHBY), Novo Nordisk, or Eli Lilly? | Categorical | | | 5 months ago | |
Will Novo Nordisk announce a new obesity drug by the end of 2024? | Binary | | | 5 months ago | |
Which company will have the largest market share in obesity drugs by the end of 2025? | Categorical | | | 5 months ago | |
Penalties or remedies in Roche vs. Stanford and Foresight lawsuit by end of 2024? | Categorical | | | 6 months ago | |
Roche settles lawsuit with Stanford and Foresight by end of 2024? | Binary | | | 6 months ago | |
Roche wins lawsuit against Stanford and Foresight by end of 2024? | Binary | | | 6 months ago | |
Will Roche announce a new partnership or acquisition in oncology by the end of 2024? | Binary | | | 6 months ago | |
Will Roche's stock price drop below $300 by the end of Q3 2024? | Binary | | | 6 months ago | |
Market reaction to Roche-Ascidian partnership announcement by June 30, 2024? | Categorical | | | 6 months ago | |
What will be the percentage increase in Roche's share price one year after the CT-388 trial announcement? | Categorical | | | 7 months ago | |
What will be Roche's rank in the global pharmaceutical market by end of 2025? | Categorical | | | 27 days ago | |
Will Roche announce another cell therapy acquisition by end of 2025? | Binary | | | 27 days ago | |
Will Merck's subcutaneous Keytruda receive FDA approval by the end of 2025? | Binary | | | 1 month ago | |
Will Merck announce a price reduction for subcutaneous Keytruda by mid-2025? | Binary | | | 1 month ago | |
Which region will see the highest adoption rate of subcutaneous Keytruda by the end of 2025? | Categorical | | | 1 month ago | |
What will be the primary factor for the adoption of subcutaneous Keytruda in clinical settings by the end of 2025? | Categorical | | | 1 month ago | |
Will Merck's subcutaneous Keytruda capture more than 30% of the PD-1/PD-L1 market share in 2025? | Binary | | | 1 month ago | |
Will Merck announce a new partnership for subcutaneous Keytruda distribution by mid-2025? | Binary | | | 1 month ago | |
What will be the market share of subcutaneous Keytruda by end of 2025? | Categorical | | | 1 month ago | |
How many countries will approve subcutaneous Keytruda by end of 2025? | Categorical | | | 1 month ago | |
Will FDA approve subcutaneous Keytruda with Berahyaluronidase Alfa by end of 2025? | Binary | | | 1 month ago | |
Will subcutaneous Keytruda surpass intravenous version in sales by end of 2026? | Binary | | | 1 month ago | |
Which significant milestone will MRT-6160 achieve by end of 2025? | Categorical | | | 2 months ago | |
What financial impact will MRT-6160 have on Novartis by end of 2025? | Categorical | | | 2 months ago | |
Will MRT-6160 progress to Phase 2 trials by end of 2025? | Binary | | | 2 months ago | |
What will be the next major strategic move by Monte Rosa by end of 2025? | Categorical | | | 2 months ago | |
Will Genentech's oncology pipeline achieve projected peak sales of $3.6 billion by December 31, 2025? | Binary | | | 3 months ago | |
Will Genentech's RGT-4198 CDK inhibitor progress to Phase 2 clinical trials by September 30, 2025? | Binary | | | 3 months ago | |
Will Genentech's RGT-4198 CDK inhibitor receive FDA Breakthrough Therapy designation by September 30, 2025? | Binary | | | 3 months ago | |
What regulatory designation will Genentech's RGT-4198 CDK inhibitor receive by September 30, 2025? | Categorical | | | 3 months ago | |
What will be the clinical trial outcome for Genentech's RGT-4198 CDK inhibitor by December 31, 2025? | Categorical | | | 3 months ago | |
What will be the next major milestone for Neuromap by end of 2024? | Categorical | | | 5 months ago | |
What will be the most cited application of Neuromap in scientific literature by end of 2024? | Categorical | | | 5 months ago | |
Will Neuromap lead to the discovery of a new neuro-target by end of 2024? | Binary | | | 5 months ago | |
Will Neuromap be featured in a peer-reviewed journal by end of 2024? | Binary | | | 5 months ago | |
Will Roche's CT-996 enter Phase II clinical trials by the end of 2024? | Binary | | | 5 months ago | |
What will be the percentage weight loss efficacy of Roche's CT-996 in Phase II trials? | Categorical | | | 5 months ago | |
Stanford and Foresight file counter-suit against Roche by end of 2024? | Binary | | | 6 months ago | |
Impact on Foresight Diagnostics' market share in cancer-detection by end of 2024? | Categorical | | | 6 months ago | |
Outcome of Roche vs. Stanford and Foresight lawsuit by end of 2024? | Categorical | | | 6 months ago | |
How will Roche's stock price performance compare to Merck's by the end of 2024? | Categorical | | | 6 months ago | |
Will Roche announce another Phase II/III lung cancer trial by the end of 2024? | Binary | | | 6 months ago | |
What will be the focus of Roche's next major drug approval by the end of 2024? | Categorical | | | 6 months ago | |
What will be the focus of Roche's next major clinical trial announcement by the end of 2024? | Categorical | | | 6 months ago | |
User Satisfaction with Roche HPV Kit One Year Post-Launch | Categorical | | | 7 months ago | |